Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma.
Patrick MartinAlisa CohenSharif UddinLaura EpelbaumSerene JosiahPublished in: Clinical ophthalmology (Auckland, N.Z.) (2020)
TAK-639 was generally well tolerated up to 0.6% BID. Further non-clinical studies will improve understanding of the MOA and the penetration of TAK-639 to the anterior chamber.